The Life Sciences team advised Palleon Pharmaceuticals on its collaboration and license agreement with Shanghai Henlius Biotech, Inc. (2696.HK) to develop and commercialize Palleon’s first-in-class human sialidase enzyme therapeutic, E-602, in combination with Henlius’ self-developed HANLIKANG (rituximab) in patients with autoimmune diseases, including lupus nephritis (LN).
Palleon is a leading biotechnology company developing drugs that harness glyco-immunology to treat cancer and inflammatory diseases. Palleon’s EAGLE (Enzyme-Antibody GLycan Editing) platform enables new target discovery, patient selection, and the development of novel therapeutics for devastating diseases characterized by immune system dysfunction. Palleon’s lead program, E-602, is a first-in-class human sialidase enzyme therapeutic developed from the company’s EAGLE platform.
Under the terms of the agreement, Henlius received an exclusive China license to Palleon’s E-602. Palleon is eligible to receive up to $95.3 million in certain predetermined development and commercial milestones, in addition to royalties upon E-602 commercialization in China. Henlius shall perform and fund E-602 development in China in combination with HANLIKANG for the treatment of LN. This partnership expands upon Palleon and Henlius’ ongoing collaboration in oncology formed in June 2022 to co-develop targeted sialidase therapies in cancer, in which collaboration Goodwin also represented Palleon.
The Goodwin team was led by Can Cui, with support from Xiaowei Wu.
For more details, read the press release and articles in Businesswire, and BioSpace.